SHARON HILL: Open Payments
NPI 1861484479 · CULLMAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$661 in 25 payments from 11 companies in 2025. Trend: 2023 $393 · 2024 $1,031 · 2025 $661
Food & beverage: $661
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 3 | $190 |
| Novartis Pharmaceuticals Corporation | 4 | $87 |
| Amgen Inc. | 4 | $76 |
| LEO Pharma Inc. | 2 | $53 |
| Incyte Corporation | 2 | $51 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $51 |
| ABBVIE INC. | 2 | $40 |
| Galderma Laboratories, L.P. | 2 | $38 |
| UCB, Inc. | 1 | $31 |
| Organon LLC | 2 | $23 |
Products named: DUPIXENT, OTEZLA, ADBRY, Opzelura, SKYRIZI, COSENTYX, NEMLUVIO, Bimzelx.
Industry payments across AL — which companies pay providers there.
